Piper Jaffray Companies Reiterates $159.00 Price Target for Shire PLC (SHPG)
Piper Jaffray Companies set a $159.00 price objective on Shire PLC (NASDAQ:SHPG) in a research note released on Wednesday morning. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
SHPG has been the subject of a number of other reports. Zacks Investment Research lowered Shire PLC from a hold rating to a sell rating in a report on Monday, July 17th. Sanford C. Bernstein lowered Shire PLC from an outperform rating to a market perform rating and decreased their price objective for the stock from $209.22 to $161.09 in a report on Thursday, May 25th. HSBC Holdings plc lowered Shire PLC from a hold rating to a reduce rating in a report on Friday, May 19th. Goldman Sachs Group, Inc. (The) increased their price target on Shire PLC from $202.00 to $214.00 and gave the company an overweight rating in a research note on Monday, April 17th. Finally, Jefferies Group LLC set a $239.00 price target on Shire PLC and gave the company a buy rating in a research note on Thursday, April 20th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $223.64.
Shares of Shire PLC (NASDAQ:SHPG) opened at 168.29 on Wednesday. Shire PLC has a 12-month low of $158.54 and a 12-month high of $209.22.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.22 by $0.41. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The business had revenue of $3.57 billion during the quarter. During the same period last year, the company earned $2.12 earnings per share. The business’s quarterly revenue was up 109.0% compared to the same quarter last year. Analysts forecast that Shire PLC will post $14.78 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Reiterates $159.00 Price Target for Shire PLC (SHPG)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-159-00-price-target-for-shire-plc-shpg/1462187.html.
Large investors have recently made changes to their positions in the stock. Whittier Trust Co. increased its stake in shares of Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 92 shares during the period. Pinnacle Bank acquired a new stake in Shire PLC during the first quarter worth about $101,000. Hartford Financial Management Inc. raised its stake in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the last quarter. Thompson Davis & CO. Inc. raised its stake in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the last quarter. Finally, FTB Advisors Inc. raised its stake in Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 75 shares during the last quarter. Institutional investors own 21.06% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.